[PDF][PDF] Review on epidermal growth factor receptor (EGFR) structure, signaling pathways, interactions, and recent updates of EGFR inhibitors

DA Sabbah, R Hajjo, K Sweidan - Current topics in medicinal …, 2020 - researchgate.net
The epidermal growth factor receptor (EGFR) belongs to the ERBB family of tyrosine kinase
receptors. EGFR signaling cascade is a key regulator in cell proliferation, differentiation …

Autocrine, paracrine and juxtacrine signaling by EGFR ligands

AB Singh, RC Harris - Cellular signalling, 2005 - Elsevier
Receptor and cytoplasmic protein tyrosine kinases play prominent roles in the control of a
range of cellular processes during embryonic development and in the regulation of many …

Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway

HW Lo, SC Hsu, M Ali-Seyed, M Gunduz, W Xia, Y Wei… - Cancer cell, 2005 - cell.com
Epidermal growth factor receptor (EGFR) exists in the nucleus of highly proliferative cells
where it functions as a transcription factor. Although EGFR has transactivational activity, it …

Dysregulation of growth factor signaling in human hepatocellular carcinoma

K Breuhahn, T Longerich, P Schirmacher - Oncogene, 2006 - nature.com
Dysregulation of pleiotropic growth factors, receptors and their downstream signaling
pathway components represent a central protumorigenic principle in human …

Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections

D Atkins, KA Reiffen, CL Tegtmeier… - … of Histochemistry & …, 2004 - journals.sagepub.com
The epidermal growth factor receptor (EGFR) is highly expressed in a variety of solid
malignant tumors and its expression has been correlated with disease progression and poor …

Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors

PM Smith-Jones, DB Solit, T Akhurst, F Afroze… - Nature …, 2004 - nature.com
The development of therapeutic inhibitors of key signaling pathways has been hampered by
the inability to assess the effect of a drug on its target in the patient. 17 …

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR) combining anti-EGFR antibody with tyrosine kinase inhibitor

S Huang, EA Armstrong, S Benavente, P Chinnaiyan… - Cancer research, 2004 - AACR
Molecular inhibition of epidermal growth factor receptor (EGFR/HER1) signaling is under
active investigation as a promising cancer treatment strategy. We examined the potency of …

Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody

W Cai, K Chen, L He, Q Cao, A Koong… - European journal of …, 2007 - Springer
Purpose Cetuximab, a chimeric monoclonal antibody targeting epidermal growth factor
receptor (EGFR) on the surface of cancer cells, was approved by the FDA to treat patients …

The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications

M Zimmermann, A Zouhair, D Azria, M Ozsahin - Radiation oncology, 2006 - Springer
Epidermal growth factor receptor (EGFR) is a member of the ErbB family of receptors. Its
stimulation by endogenous ligands, EGF or transforming growth factor-alpha (TGF-α) results …

EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization

HW Lo, SC Hsu, MC Hung - Breast cancer research and treatment, 2006 - Springer
Aberrant epidermal growth factor receptor (EGFR) signaling is a major characteristic of many
human malignancies including breast cancer. Since the discovery of EGF in 1960's and its …